

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5609971

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	KENNETH SOKOLL	01/13/2017
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	VASOMUNE THERAPEUTICS INC.	
<b>Street Address:</b>	180 JOHN STREET	
<b>Internal Address:</b>	SUITE 305	
<b>City:</b>	TORONTO	
<b>State/Country:</b>	CANADA	
<b>Postal Code:</b>	M5T 1X5	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	16476750
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(416)361-1398	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	416.364.7311	
<b>Email:</b>	msuong@bereskinparr.com	
<b>Correspondent Name:</b>	BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.	
<b>Address Line 1:</b>	40 KING STREET WEST	
<b>Address Line 2:</b>	40TH FLOOR	
<b>Address Line 4:</b>	TORONTO, CANADA M5H 3Y2	
<b>ATTORNEY DOCKET NUMBER:</b>	23632-P52201US01	
<b>NAME OF SUBMITTER:</b>	MELANIE SZWERAS	
<b>SIGNATURE:</b>	/Melanie Szweras/	
<b>DATE SIGNED:</b>	07/09/2019	
<b>Total Attachments: 3</b>		
source=KennethSokoll_to_Vasomune_Assignment_Executed#page1.tif		
source=KennethSokoll_to_Vasomune_Assignment_Executed#page2.tif		
source=KennethSokoll_to_Vasomune_Assignment_Executed#page3.tif		



## **ASSIGNMENT OF RIGHTS TO VASOMUNE THERAPEUTICS BY THE INVENTOR**

In consideration of the sum of two dollars (\$2.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, **Kenneth Sokoll**, his heirs, executors, administrators and assigns (collectively the "Assignor") hereby sells, assigns and transfers to Vasomune Therapeutics Inc., its successors and assigns (collectively the "Assignee") all right, title and interest which the Assignor now has or may hereafter have in an invention described as

### **Vasculotide variants: novel compositions of matter and uses thereof**

in Appendix A annexed hereto (the "Invention"; or previously provided Invention Disclosure form **SB 2015-025**), including, without limitation, the right to apply for patents in Canada, the United States of America and any other country, the right to receive any letters patent that may be issued from any such applications, the right to have any letters patent that have been granted transferred into the name of the Assignee, and the right to sell, license or assign the Invention or the rights thereto.

The Assignor hereby releases the Assignee from any and all manner of claims and demands which the Assignor may now have or may in future have in respect of the Invention or in connection with the patenting, sale or licensing thereof.

The Assignor agrees to execute any additional documents that the Assignee may consider necessary or desirable from time to time in order to obtain, maintain, vest in or assign title to the Invention or any patents, copyright, integrated circuit topography, industrial design or trade mark registrations for the Invention; or in order to apply for, prosecute, obtain or protect any such patents, copyright, integrated circuit topography, industrial design or trade mark registrations in any and all jurisdictions.

The parties agree that each has been advised to and given the opportunity to seek independent legal advice before signing this Agreement, and that neither has relied upon the other party for advice (whether legal or otherwise) with respect to this Agreement. This Agreement contains the entire understanding between the parties and supersedes any previous understandings or agreements, written or oral, concerning this matter.

This agreement may be executed by signatures delivered by facsimile transmission or delivered electronically in optically scanned form; and/or it may be simultaneously executed by the parties in multiple counterparts, each of which will be considered to be an original instrument, and all of which taken together, where each party has executed at least one counterpart, will constitute one and the same instrument.

*[Illegible handwritten text]*

*[Signature]*  
Michael Midmer  
Chief Executive Officer  
Jan 13 / 17

